Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew D Zelenetz

Showing results (1-10 of 235) with videos related to

Pageof 24
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|May 22, 2015
Emerging treatment options for B-cell lymphomasAndrew D Zelenetz
Oncology (Williston Park, N.Y.)|December 20, 2003
Risk models for chemotherapy-induced neutropenia in non-Hodgkin's lymphomaAndrew D Zelenetz
Clinical Advances in Hematology & Oncology : H&O|March 3, 2023
Zandelisib and B-cell lymphomasAndrew D Zelenetz
Clinical Advances in Hematology & Oncology : H&O|November 14, 2007
Will radioimmunotherapy survive?Andrew D Zelenetz
Journal of the National Comprehensive Cancer Network : JNCCN|November 26, 2019
The Era of Therapeutic Biosimilars Has Arrived: What You Need to KnowAndrew D Zelenetz
Journal of the National Comprehensive Cancer Network : JNCCN|January 15, 2011
Lessons from ASH 2010: a focus on NHLAndrew D Zelenetz
Seminars in Oncology|May 3, 2003
A clinical and scientific overview of tositumomab and iodine I 131 tositumomabAndrew D Zelenetz
Journal of the National Comprehensive Cancer Network : JNCCN|May 19, 2017
Chronic Lymphocytic Leukemia: Individualizing Treatment ApproachAndrew D Zelenetz
Clinical Lymphoma & Myeloma|November 1, 2008
Lymphoid malignancies: a decade and a half of dramatic improvements in outcomeAndrew D Zelenetz
Journal of the National Comprehensive Cancer Network : JNCCN|October 3, 2009
Non-Hodgkin's lymphoma clinical practice guidelinesAndrew D Zelenetz,
Pageof 24

Showing results (1-10 of 235) with videos related to

Sort By:
Pageof 24
Journal of the National Comprehensive Cancer Network : JNCCN|May 22, 2015
Emerging treatment options for B-cell lymphomasAndrew D Zelenetz
Oncology (Williston Park, N.Y.)|December 20, 2003
Risk models for chemotherapy-induced neutropenia in non-Hodgkin's lymphomaAndrew D Zelenetz
Clinical Advances in Hematology & Oncology : H&O|March 3, 2023
Zandelisib and B-cell lymphomasAndrew D Zelenetz
Clinical Advances in Hematology & Oncology : H&O|November 14, 2007
Will radioimmunotherapy survive?Andrew D Zelenetz
Journal of the National Comprehensive Cancer Network : JNCCN|November 26, 2019
The Era of Therapeutic Biosimilars Has Arrived: What You Need to KnowAndrew D Zelenetz
Journal of the National Comprehensive Cancer Network : JNCCN|January 15, 2011
Lessons from ASH 2010: a focus on NHLAndrew D Zelenetz
Seminars in Oncology|May 3, 2003
A clinical and scientific overview of tositumomab and iodine I 131 tositumomabAndrew D Zelenetz
Journal of the National Comprehensive Cancer Network : JNCCN|May 19, 2017
Chronic Lymphocytic Leukemia: Individualizing Treatment ApproachAndrew D Zelenetz
Clinical Lymphoma & Myeloma|November 1, 2008
Lymphoid malignancies: a decade and a half of dramatic improvements in outcomeAndrew D Zelenetz
Journal of the National Comprehensive Cancer Network : JNCCN|October 3, 2009
Non-Hodgkin's lymphoma clinical practice guidelinesAndrew D Zelenetz,
Pageof 24